Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 143

1.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG.

N Engl J Med. 2017 Nov 9;377(19):1836-1846. doi: 10.1056/NEJMoa1701830.

PMID:
29117498
2.

Improving Breast Ultrasound Interpretation in Uganda Using a Condensed Breast Imaging Reporting and Data System.

Scheel JR, Peacock S, Orem J, Bugeza S, Muyinda Z, Porter PL, Wood WC, Comis RL, Lehman CD.

Acad Radiol. 2016 Oct;23(10):1271-7. doi: 10.1016/j.acra.2016.05.018. Epub 2016 Jun 17.

PMID:
27325412
3.

Opportunities for the ECOG-ACRIN Cancer Research Group within the new National Clinical Trials Network.

Comis RL, Schnall MD.

Semin Oncol. 2015 Feb;42(1):1-3. doi: 10.1053/j.seminoncol.2014.12.017. Epub 2014 Dec 20. No abstract available.

PMID:
25726046
4.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.

Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848.

5.

The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.

Denicoff AM, McCaskill-Stevens W, Grubbs SS, Bruinooge SS, Comis RL, Devine P, Dilts DM, Duff ME, Ford JG, Joffe S, Schapira L, Weinfurt KP, Michaels M, Raghavan D, Richmond ES, Zon R, Albrecht TL, Bookman MA, Dowlati A, Enos RA, Fouad MN, Good M, Hicks WJ, Loehrer PJ Sr, Lyss AP, Wolff SN, Wujcik DM, Meropol NJ.

J Oncol Pract. 2013 Nov;9(6):267-76. doi: 10.1200/JOP.2013.001119. Epub 2013 Oct 15.

6.

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R.

Lancet. 2011 Nov 12;378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Review.

7.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R.

Lancet. 2011 Aug 27;378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.

8.

Measuring cancer clinical trial understanding.

Miller JD, Kotowski MR, Comis RL, Smith SW, Silk KJ, Colaizzi DD, Kimmel LG.

Health Commun. 2011 Jan;26(1):82-93. doi: 10.1080/10410236.2011.527624.

PMID:
21218302
9.

A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer.

Obasaju CK, Ansari RH, Socinski MA, Chen R, Monberg MJ, Catalano RB, Marinucci DM, Liles DK, Ribeiro MJ, Comis RL, Treat J; Alpha Oncology Research Network.

J Thorac Oncol. 2010 Jul;5(7):993-1000.

10.

A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.

Ansari RH, Socinski MA, Edelman MJ, Belani CP, Gonin R, Catalano RB, Marinucci DM, Comis RL, Obasaju CK, Chen R, Monberg MJ, Treat J; Alpha Oncology Research Network.

Crit Rev Oncol Hematol. 2011 May;78(2):162-71. doi: 10.1016/j.critrevonc.2010.03.003. Epub 2010 Apr 21.

PMID:
20413322
11.

Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy.

Sparano JA, Pisano ED, White JR, Hunt KK, Mamounas EP, Perez EA, Hortobagyi GN, Gralow JR, Comis RL.

Breast Cancer Res Treat. 2010 Apr;120(2):273-84. doi: 10.1007/s10549-009-0655-z. Epub 2009 Dec 19. Review.

PMID:
20024613
12.

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.

Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM, Ansari R, Gillenwater HH, Rowland KM, Comis RL, Obasaju CK, Belani CP; Alpha Oncology Research Network.

Ann Oncol. 2010 Mar;21(3):540-7. doi: 10.1093/annonc/mdp352. Epub 2009 Oct 15.

PMID:
19833819
13.

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.

Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL.

J Clin Oncol. 2009 Oct 20;27(30):4966-72. doi: 10.1200/JCO.2008.21.6630. Epub 2009 Aug 31.

14.

Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization.

Sparano JA, Hortobagyi GN, Gralow JR, Perez EA, Comis RL.

Breast Cancer Res Treat. 2010 Feb;119(3):511-27. doi: 10.1007/s10549-009-0433-y. Epub 2009 Jun 14.

PMID:
19526354
15.

Adjuvant chemotherapy in older women with early-stage breast cancer.

Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP; CALGB Investigators.

N Engl J Med. 2009 May 14;360(20):2055-65. doi: 10.1056/NEJMoa0810266. Erratum in: N Engl J Med. 2009 Oct 22;361(17):1714. Magrinat, Gutav [corrected to Magrinat, Gustav].

16.

Physician-related factors involved in patient decisions to enroll onto cancer clinical trials.

Comis RL, Miller JD, Colaizzi DD, Kimmel LG.

J Oncol Pract. 2009 Mar;5(2):50-6. doi: 10.1200/JOP.0922001.

17.

The role of the Eastern Cooperative Oncology Group in establishing standards of cancer care: over 50 years of progress through clinical research.

Giantonio BJ, Forastiere AA, Comis RL; Eastern Cooperative Oncology Group.

Semin Oncol. 2008 Oct;35(5):494-506. doi: 10.1053/j.seminoncol.2008.07.004. Review.

PMID:
18929148
18.

Introduction: contributions of the cooperative groups.

Perry MC, Comis RL, Schilsky RL.

Semin Oncol. 2008 Oct;35(5):459. doi: 10.1053/j.seminoncol.2008.07.003. No abstract available.

PMID:
18929144
19.

Addressing the current challenges of non-small-cell lung cancer clinical trial accrual.

Curran WJ Jr, Schiller JH, Wolkin AC, Comis RL; Scientific Leadership Council in Lung Cancer of the Coalition of Cancer Cooperative Groups.

Clin Lung Cancer. 2008 Jul;9(4):222-6. doi: 10.3816/CLC.2008.n.033. Review.

PMID:
18650170
20.

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.

Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA; Eastern Cooperative Oncology Group.

Ann Oncol. 2008 May;19(5):977-83. doi: 10.1093/annonc/mdm591. Epub 2008 Feb 21.

PMID:
18296423

Supplemental Content

Loading ...
Support Center